Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Source: SeekingAlpha
2026-05-30 13:46:37 ET
More on Incyte, Xencor
- Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
- Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
- Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Incyte-Genesis expands AI drug discovery deal with $120M funding and new targets
- Xencor GAAP EPS of -$1.71 misses by $0.96, revenue of $4.51M misses by $22.16M
Read the full article on Seeking Alpha
For further details see:
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Johnson & Johnson
NASDAQ: JNJ
JNJ Trading
1.56% G/L:
$227.57 Last:
2,600,450 Volume:
$227.09 Open:
JNJ Latest News
JNJ Stock Data
$577,845,337,264
2,385,202,151
0.01%
2802
N/A
Pharmaceuticals
Healthcare
US
New Brunswick
